Jacobs Levy Equity Management, Inc Arvinas, Inc. Transaction History
Jacobs Levy Equity Management, Inc
- $23.9 Billion
- Q1 2025
A detailed history of Jacobs Levy Equity Management, Inc transactions in Arvinas, Inc. stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 42,810 shares of ARVN stock, worth $278,693. This represents 0.0% of its overall portfolio holdings.
Number of Shares
42,810Holding current value
$278,693% of portfolio
0.0%Shares
7 transactions
Others Institutions Holding ARVN
# of Institutions
246Shares Held
62.5MCall Options Held
2.65MPut Options Held
1.1M-
Vanguard Group Inc Valley Forge, PA8.36MShares$54.4 Million0.0% of portfolio
-
Black Rock Inc. New York, NY6.26MShares$40.7 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il3.88MShares$25.2 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.83MShares$24.9 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY3.33MShares$21.7 Million0.38% of portfolio
About ARVINAS, INC.
- Ticker ARVN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,205,300
- Market Cap $346M
- Description
- Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...